AMBITION (High Dose AMBISOME on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomised Controlled Non-inferiority Trial) is a four-year project funded at just under €10M by the European and Developing Countries Clinical Trials Partnership, the Swedish International Development Agency and the DFID/MRC/Wellcome Trust Joint Global Health Trials Fund. It runs from 1 January 2017 – 31 December 2020 across a consortium of five European and six African partners.
The Phase III clinical trial will recruit 850 patients at our six African sites. It is the largest clinical trial for HIV-associated cryptococcal meningitis ever to be conducted.
A number of other activities run alongside the trial, including economic cost-effectiveness analyses, laboratory-based sub-studies, and training and capacity building events. An African Meningitis Trials Network (AMTNET) has also been established, which seeks to provide a framework for future clinical trials to investigate urgently needed novel treatments and diagnostics strategies aimed at reducing the morbidity and mortality due to meningitis in Africa. It is envisaged that AMTNET will continue to operate long after completion of AMBITION.
AMBITION is co-ordinated by The London School of Hygiene and Tropical Medicine, UK. Our African collaborating institutions and recruiting sites are shown below.